Previous 10 | Next 10 |
Marinus Pharmaceuticals ( NASDAQ: MRNS ) said the Biomedical Advanced Research and Development Authority (BARDA) exercised its first contract option worth ~$12.3M, to support U.S. onshoring of manufacturing capabilities for seizure therapy ganaxolone active pharmaceutic...
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Pr...
Marinus Pharmaceuticals ( NASDAQ: MRNS ) on Monday said it had closed on the sale of a U.S. FDA voucher for $110M. The voucher, called the Rare Pediatric Disease Priority Review Voucher, entitles MRNS to a priority review from the agency and proceeds to carry out its d...
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has closed on the sale of its Rare Pediatric Disease Priority Review Voucher for $110 million. The $110...
Marinus Pharmaceuticals, Inc. (MRNS) Q2 2022 Earnings Conference Call August 11, 2022, 08:30 ET Company Participants Sasha Ellis - VP, Corporate Affairs & IR Scott Braunstein - CEO, President & Director Christy Shafer - Chief Commercial Officer Joseph...
Marinus Pharmaceuticals press release ( NASDAQ: MRNS ): Q2 GAAP EPS of -$1.06 misses by $0.37 . Revenue of $1.8M (-5.8% Y/Y) misses by $0.51M . GUIDANCE For the fiscal year 2022, the Company expects BARDA revenues in the range of $7 to $10 million and total...
ZTALMY ® can now be prescribed by healthcare professionals in the U.S. Second generation ganaxolone formulation demonstrates encouraging results in Phase 1 study in healthy volunteers and supports further clinical development Marinus’ Phase 2 refractory status ...
Marinus Pharmaceuticals ( NASDAQ: MRNS ) is scheduled to announce Q2 earnings results on Thursday, August 11th, before market open. The consensus EPS Estimate is -$0.93 (-43.1% Y/Y) and the consensus Revenue Estimate is $2.31M (+20.9% Y/Y). Over the last 3 months, EPS ...
Major earnings expected before the bell on Thursday include: Arrival ( ARVL ) Brookfield Asset Management ( BAM ) Cardinal Health ( CAH ) Hanesbrands ( HBI ) Himax Technologies ( HIMX ) For further details see: Notable earnings before Thur...
Marinus Pharmaceuticals ( NASDAQ: MRNS ) on Thursday announced the U.S. commercial launch of Ztalmy for the treatment of seizures associated with CDKL5 deficiency disorder (CDD) in patients aged two years and older. CDD is a genetic disorder caused due to mutations in ...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on August 13, 2024. The Company will h...
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law Firm PR Newswire LOS ANGELES , July 24, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing ...
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...